original ) (raw )Cell-based vaccination against melanoma – background, preliminary results, and perspective
Dirk Schadendorf
Journal of Molecular Medicine, 1999
View PDFchevron_right
Dendritic cell-based vaccine in advanced melanoma
Emanuela Scarpi
Melanoma Research, 2011
View PDFchevron_right
Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein
Javier Carrasco Carrasco
The Journal of Immunology, 2005
View PDFchevron_right
Melanoma and immunotherapy bridge 2015
Angel Rivera
Journal of Translational Medicine, 2016
View PDFchevron_right
Immunotherapy Outcomes in Advanced Melanoma in Relation to Age
Issam Makhoul
The Permanente Journal, 2020
View PDFchevron_right
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Jon Kyte
Cancer Immunology, Immunotherapy, 2006
View PDFchevron_right
Active Immunization of Metastatic Melanoma Patients with Interleukin4 Transduced, Allogeneic Melanoma Cells. A Phase I–II Study. University of Turin, Italy
Mario Colombo
Human Gene Therapy, 1994
View PDFchevron_right
Adoptive Immunotherapy with Cl-IB-MECA-Treated CD8+ T Cells Reduces Melanoma Growth in Mice
Giovanni Forte
PLoS ONE, 2012
View PDFchevron_right
Prognostic value of quantitative immune alterations in melanoma patients
A. Tres
Oncología (Barcelona), 2006
View PDFchevron_right
Outcomes of Immunosuppressed Patients Who Develop Melanoma: A Population-Based Propensity-Matched Cohort Study
Janice Austin
Annals of Surgical Oncology, 2020
View PDFchevron_right
Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient
Luis Real
Cancer Immunology, Immunotherapy, 2001
View PDFchevron_right
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
Genny Del Zotto
Journal of Translational Medicine, 2018
View PDFchevron_right
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels
Rudolf Morant
Cancer Gene Therapy, 2002
View PDFchevron_right
Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients
asma gati
Cancer Immunology, Immunotherapy, 2006
View PDFchevron_right
Cancer Immunotherapy: A Systemic Review
Ashesh Chowdhury
Archives of oncology and cancer therapy, 2024
View PDFchevron_right
Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Markus Frank
2023
View PDFchevron_right
Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo
Véronique Flamand
Journal of Immunology, 1990
View PDFchevron_right
Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Markus Frank
2023
View PDFchevron_right
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells
Ji-li Chen
International Journal of Cancer, 2000
View PDFchevron_right
Cancer Vaccines and Tumor Immunity
Veronica Preda
2007
View PDFchevron_right
Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study
Janice Austin
Annals of Surgical Oncology, 2020
View PDFchevron_right
Current clinical trials for melanoma vaccines: where do we stand?
Erika Bisgaard
Melanoma Management, 2016
View PDFchevron_right
Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma
Robert Lew
Cancer, 2010
View PDFchevron_right
Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103−and XCR1+CD103+dendritic cells
Rachael Zemek
OncoImmunology, 2015
View PDFchevron_right
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts
Vincenzo Montesarchio
Journal of Translational Medicine
View PDFchevron_right
Biological therapy in the treatment of melanoma
Mihaela Ioghen
Journal of Mind and Medical Sciences, 2018
View PDFchevron_right
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
Olga Vornicova
International Journal of Molecular Sciences, 2023
View PDFchevron_right
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
Lea Eisenbach
Cell, 2019
View PDFchevron_right
Melanoma vaccines: The problems of local immunosuppression
Nicola Borthwick
Human Immunology, 2009
View PDFchevron_right
Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Jens Kiilgaard
Annals of Oncology, 2019
View PDFchevron_right
Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells
William Mcbride
Cancer Gene Therapy, 1999
View PDFchevron_right
Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma
Craig Slingluff
Annals of Surgical Oncology, 2014
View PDFchevron_right
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability
Mario Colombo
Cancer Immunology Immunotherapy, 1997
View PDFchevron_right
Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Jonathan Treisman
2011
View PDFchevron_right
Local irradiation of murine melanoma affects the development of tumour-specific immunity
William Mcbride
Immunology, 2009
View PDFchevron_right